- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BIIB
Recent news which mentions BIIB
3 Unstoppable Stocks to Buy for 2022
December 23, 2021
From Motley Fool
Eisai shares sink after Japan regulators seek more data for review of Alzheimer’s drug
December 22, 2021
Tickers
BIIB
From MarketWatch
From InvestorPlace
10 Biggest Price Target Changes For Wednesday
December 22, 2021
From Benzinga
Got $1,000? These 3 Stocks Are Still Absurdly Cheap
December 22, 2021
From Motley Fool
Biogen’s decision to halve price of Alzheimer’s drug is ‘a day late and a dollar short,’ says Raymond James
December 20, 2021
From MarketWatch
After Much Criticism, Biogen Slashes Aduhelm Price In Half
December 20, 2021
Tickers
BIIB
From Benzinga
10 Biggest Price Target Changes For Monday
December 20, 2021
From Benzinga
EMA's Committee Gives Thumbs Down To Biogen's Controversial Alzheimer's Drug, As Expected
December 17, 2021
Tickers
BIIB
From Benzinga
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
December 17, 2021
From Benzinga
From Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
From Benzinga
More Specificity is What the Doctor Ordered
December 14, 2021
From Benzinga
‘Grandma and grandpa aren’t going to figure this one out.’ Prescription-drug savings vanish in the Medicare shuffle
December 10, 2021
From MarketWatch
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
From Benzinga
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
December 08, 2021
From Benzinga
Early Clinical Data Suggest This New Lotion Could Offer Best-In-Class Eczema Treatment and Infection Prevention, According to Hoth Therapeutics
December 07, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
December 06, 2021
From Benzinga
Should You Blame Biogen for Medicare Part B Premium Hikes?
December 03, 2021
Tickers
BIIB
From Motley Fool
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
December 01, 2021
From Benzinga
From Benzinga
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
November 30, 2021
From Benzinga
Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?
November 28, 2021
From Motley Fool
2 Moonshot Biotechs with 10x Potential
November 22, 2021
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.